Neoepitopes as biomarkers of cartilage catabolism - PubMed (original) (raw)
Neoepitopes as biomarkers of cartilage catabolism
A J Fosang et al. Inflamm Res. 2003 Jun.
Abstract
Progressive degradation of articular cartilage is a central feature of arthritis and a major determinant of long term joint dysfunction. There are no treatments able to halt the progression of cartilage destruction presently available, and monitoring the benefit of potential therapies is hampered by our inability to measure the "health" of articular cartilage. Serial radiographic assessment of joint space narrowing, the current gold standard, requires measurements over a prolonged time (1-5 years) and is prone to technical difficulties. Other strategies for evaluating cartilage degradation are needed to enable both short and long term monitoring of disease progression and response to therapy. One avenue that holds promise is the use of biomarkers that accurately reflect the degradative state of the articular cartilage. Antibodies that recognise terminal amino acid sequences generated by proteolysis at specific sites in the core protein of both aggrecan and type II collagen (neoepitope antibodies) have become available in recent years. These antibodies have been invaluable for identifying the proteinases responsible for cartilage breakdown both in vitro and in vivo. The presence of neoepitope sequences generated by specific metalloenzyme cleavage of aggrecan and type II collagen correlates well with the progression of cartilage degeneration, both in vitro and in mouse models of arthritis. Preliminary results with quantitative assays of type II collagen neoepitopes suggest that they may be useful markers of joint disease in humans. Long term studies correlating neoepitope concentration with clinical and radiographic disease are now required to validate the utility of neoepitopes as surrogate markers of cartilage degeneration and joint disease.
Similar articles
- Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration.
Janusz MJ, Little CB, King LE, Hookfin EB, Brown KK, Heitmeyer SA, Caterson B, Poole AR, Taiwo YO. Janusz MJ, et al. Osteoarthritis Cartilage. 2004 Sep;12(9):720-8. doi: 10.1016/j.joca.2004.06.004. Osteoarthritis Cartilage. 2004. PMID: 15325638 - Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.
Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, Singer II, Donatelli SA, Weidner JR, Williams HR, Mumford RA, Lohmander LS. Lark MW, et al. J Clin Invest. 1997 Jul 1;100(1):93-106. doi: 10.1172/JCI119526. J Clin Invest. 1997. PMID: 9202061 Free PMC article. - Mechanisms involved in cartilage proteoglycan catabolism.
Caterson B, Flannery CR, Hughes CE, Little CB. Caterson B, et al. Matrix Biol. 2000 Aug;19(4):333-44. doi: 10.1016/s0945-053x(00)00078-0. Matrix Biol. 2000. PMID: 10963994 Review. - Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity.
van Meurs J, van Lent P, Stoop R, Holthuysen A, Singer I, Bayne E, Mudgett J, Poole R, Billinghurst C, van der Kraan P, Buma P, van den Berg W. van Meurs J, et al. Arthritis Rheum. 1999 Oct;42(10):2074-84. doi: 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5. Arthritis Rheum. 1999. PMID: 10524678 - Use of anti-neoepitope antibodies for the analysis of degradative events in cartilage and the molecular basis for neoepitope specificity.
Mort JS, Flannery CR, Makkerh J, Krupa JC, Lee ER. Mort JS, et al. Biochem Soc Symp. 2003;(70):107-14. doi: 10.1042/bss0700107. Biochem Soc Symp. 2003. PMID: 14587286 Review.
Cited by
- Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro.
Crombie DE, Turer M, Zuasti BB, Wood B, McNaughton D, Nandakumar KS, Holmdahl R, Van Damme MP, Rowley MJ. Crombie DE, et al. Arthritis Res Ther. 2005;7(5):R927-37. doi: 10.1186/ar1766. Epub 2005 Jun 6. Arthritis Res Ther. 2005. PMID: 16207334 Free PMC article. - Clinical monitoring in osteoarthritis: Biomarkers.
Kraus VB, Karsdal MA. Kraus VB, et al. Osteoarthritis Cartilage. 2022 Sep;30(9):1159-1173. doi: 10.1016/j.joca.2021.04.019. Epub 2021 Sep 16. Osteoarthritis Cartilage. 2022. PMID: 34536529 Free PMC article. - What are the roles of metalloproteinases in cartilage and bone damage?
Murphy G, Lee MH. Murphy G, et al. Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv44-7. doi: 10.1136/ard.2005.042465. Ann Rheum Dis. 2005. PMID: 16239386 Free PMC article. Review. - Usurped SLRPs: novel arthritis biomarkers exposed by catabolism of small leucine-rich proteoglycans?
Flannery CR. Flannery CR. Arthritis Res Ther. 2006;8(2):106. doi: 10.1186/ar1925. Epub 2006 Mar 13. Arthritis Res Ther. 2006. PMID: 16563183 Free PMC article. Review. - The urinary levels of CTX-II, C2C, PYD, and Helix-II increased among adults with KBD: a cross-sectional study.
Song QQ, Sun LY, Li CH, Liu YJ, Cui SL, Liu YQ, Cao YH, Pei JR, Wang Y, Lian W, Jiao Z, Deng Q, Yu J. Song QQ, et al. J Orthop Surg Res. 2019 Oct 21;14(1):328. doi: 10.1186/s13018-019-1392-6. J Orthop Surg Res. 2019. PMID: 31639015 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical